Bachem (BCHMF) Expected to Announce Earnings on Thursday

Bachem (OTCMKTS:BCHMF) is projected to post its results before the market opens on Thursday, March 12th. Analysts expect Bachem to post earnings of $1.11 per share and revenue of $466.9280 million for the quarter.

Bachem Stock Performance

Bachem stock opened at $76.77 on Thursday. Bachem has a 12 month low of $60.51 and a 12 month high of $82.73. The stock has a 50-day moving average price of $74.37 and a two-hundred day moving average price of $68.20.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Bachem in a research note on Monday, January 26th. UBS Group raised shares of Bachem to a “buy” rating in a research report on Tuesday, December 2nd. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy”.

About Bachem

Bachem Holding AG is a Switzerland‐based specialty biochemical company focused on the development, manufacturing and commercialization of peptides and oligonucleotides. Serving pharmaceutical and biotechnology clients as well as academic research institutions, the company offers a broad spectrum of products ranging from custom peptide synthesis for research applications to clinical and commercial‐grade active pharmaceutical ingredients (APIs). Bachem’s expertise extends to process development, scale‐up and GMP‐compliant production, supporting projects in therapeutic areas such as oncology, metabolic disorders and infectious diseases.

Founded in 1971 and headquartered in Bubendorf, Switzerland, Bachem has grown through strategic investments in production capacity and the acquisition of complementary peptide and oligonucleotide technologies.